Literature DB >> 26688577

VZV, temporal arteritis, and clinical practice: False positive immunohistochemical detection due to antibody cross-reactivity.

David J Pisapia1, Ehud Lavi2.   

Abstract

Varicella Zoster Virus (VZV) antigen has been reported to be present in the majority of temporal artery biopsies with implications for antiviral treatment in patients with giant cell arteritis. Using immunohistochemistry with VZV antibodies we found reactivity present in diverse myocyte types (smooth, skeletal and cardiac), diverse arteries (including temporal, coronary, and vertebral) and diverse clinical settings. This phenomenon is likely due to shared epitopes between VZV proteins and muscle elements and not due to actual VZV infection. We conclude that VZV immunohistochemistry should be used with caution for screening of VZV infection in the setting of temporal artery biopsies.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Giant cell arteritis; Myocytes; Temporal arteritis; Varicella Zoster Virus (VZV)

Mesh:

Substances:

Year:  2015        PMID: 26688577     DOI: 10.1016/j.yexmp.2015.12.007

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  9 in total

Review 1.  Update on the management of giant cell arteritis.

Authors:  Janet Roberts; Alison Clifford
Journal:  Ther Adv Chronic Dis       Date:  2017-03-28       Impact factor: 5.091

Review 2.  Highlights in clinical medicine-Giant cell arteritis, polymyalgia rheumatica and Takayasu's arteritis: pathogenic links and therapeutic implications.

Authors:  Antonio Giovanni Solimando; Angelo Vacca; Franco Dammacco
Journal:  Clin Exp Med       Date:  2021-11-06       Impact factor: 5.057

Review 3.  New Insights into the Pathogenesis of Giant Cell Arteritis: Mechanisms Involved in Maintaining Vascular Inflammation.

Authors:  Hélène Greigert; Coraline Genet; André Ramon; Bernard Bonnotte; Maxime Samson
Journal:  J Clin Med       Date:  2022-05-20       Impact factor: 4.964

4.  A new monoclonal antibody (Cox mAB 31A2) detects VP1 protein of coxsackievirus B3 with high sensitivity and specificity.

Authors:  Nicole Ettischer-Schmid; Andrea Normann; Martina Sauter; Lisa Kraft; Hubert Kalbacher; Reinhard Kandolf; Bertram Flehmig; Karin Klingel
Journal:  Virchows Arch       Date:  2016-08-27       Impact factor: 4.064

5.  Herpes Zoster as a Risk Factor for Incident Giant Cell Arteritis.

Authors:  Bryant R England; Ted R Mikuls; Fenglong Xie; Shuo Yang; Lang Chen; Jeffrey R Curtis
Journal:  Arthritis Rheumatol       Date:  2017-11-09       Impact factor: 10.995

Review 6.  Clinical Features of Varicella-Zoster Virus Infection.

Authors:  Peter G E Kennedy; Anne A Gershon
Journal:  Viruses       Date:  2018-11-02       Impact factor: 5.048

Review 7.  One Giant Step for Giant Cell Arteritis: Updates in Diagnosis and Treatment.

Authors:  Marc Dinkin; Editha Johnson
Journal:  Curr Treat Options Neurol       Date:  2021-01-16       Impact factor: 3.598

8.  No Evidence of Varicella-Zoster Virus Infection in Temporal Artery Biopsies of Anterior Ischemic Optic Neuropathy Patients With and Without Giant Cell Arteritis.

Authors:  Robert M Verdijk; Werner J D Ouwendijk; Robert W A M Kuijpers; Georges M G M Verjans
Journal:  J Infect Dis       Date:  2021-01-04       Impact factor: 5.226

9.  Does herpes zoster predispose to giant cell arteritis: a geo-epidemiologic study.

Authors:  Edsel B Ing; Royce Ing; Xinyang Liu; Angela Zhang; Nurhan Torun; Michael Sey; Christian Pagnoux
Journal:  Clin Ophthalmol       Date:  2018-01-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.